CD79A and COVID-19: In all four tests, diagnostic performance improved with the time of infection, and sensitivity increased over time, reaching 87% for the Anti-SARS-CoV-2 NCP IgM ELISA and the Anti-SARS-CoV-2 IgG ELISA, 95.7% for the IBMP Spike IgA/IgM/IgG ELISA, and 100% for the GOLD ELISA COVID-19 IgG/IgM.